Search research articles
Contact Us
Filters
Showing results (41-50 of 134) with videos related to
Page
of 14
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
July 3, 2007
Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck
Lars Bastholt, Lena Specht, Kenneth Jensen, et al.
Acta Oncologica (Stockholm, Sweden)
|
April 30, 2013
Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma
Yvonne Brandberg, Hemming Johansson, Steinar Aamdal, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 16, 2024
Does patient sex affect the treatment outcome of immune checkpoint inhibitors? A Danish, observational melanoma study
Soeren Kjaer Petersen, Christian Rønn Hansen, Eva Ellebaek, et al.
The Lancet. Oncology
|
January 25, 2011
Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial
Johan Hansson, Steinar Aamdal, Lars Bastholt, et al.
Anticancer Research
|
February 7, 2016
Gene-expression Classifier in Papillary Thyroid Carcinoma: Validation and Application of a Classifier for Prognostication
Stefano Christian Londero, Marie Louise Jespersen, Annelise Krogdahl, et al.
The Journal of Clinical Endocrinology and Metabolism
|
June 15, 2007
Improvement of goiter volume reduction after 0.3 mg recombinant human thyrotropin-stimulated radioiodine therapy in patients with a very large goiter: a double-blinded, randomized trial
Steen J Bonnema, Viveque E Nielsen, Henrik Boel-Jørgensen, et al.
The Journal of Clinical Endocrinology and Metabolism
|
July 31, 2008
Recombinant human thyrotropin-stimulated radioiodine therapy of large nodular goiters facilitates tracheal decompression and improves inspiration
Steen J Bonnema, Viveque E Nielsen, Henrik Boel-Jørgensen, et al.
British Journal of Cancer
|
May 26, 2025
Long-term clinical outcome of patients with metastatic melanoma and initial stable disease during anti-PD-1 checkpoint inhibitor immunotherapy with pembrolizumab
Inge Mansfield Noringriis, Marco Donia, Kasper Madsen, et al.
American Journal of Therapeutics
|
November 5, 2013
Side effects and toxicities of targeted therapies in stage IV melanoma
Paolo A Ascierto, Lars Bastholt, Peter Hersey, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 13, 2025
Impact of assessment-to-treatment interval and metastatic biopsy site on the predictive value of PD-L1 expression at the 1 % cut-off level in melanoma
Cecilie D Vestergaard, Marco Donia, Kasper Madsen, et al.
Page
of 14
Search research articles
Search
Showing results (41-50 of 134) with videos related to
Sort By:
Page
of 14
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
July 3, 2007
Phase I/II clinical and pharmacokinetic study evaluating a fully human monoclonal antibody against EGFr (HuMax-EGFr) in patients with advanced squamous cell carcinoma of the head and neck
Lars Bastholt, Lena Specht, Kenneth Jensen, et al.
Acta Oncologica (Stockholm, Sweden)
|
April 30, 2013
Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma
Yvonne Brandberg, Hemming Johansson, Steinar Aamdal, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 16, 2024
Does patient sex affect the treatment outcome of immune checkpoint inhibitors? A Danish, observational melanoma study
Soeren Kjaer Petersen, Christian Rønn Hansen, Eva Ellebaek, et al.
The Lancet. Oncology
|
January 25, 2011
Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial
Johan Hansson, Steinar Aamdal, Lars Bastholt, et al.
Anticancer Research
|
February 7, 2016
Gene-expression Classifier in Papillary Thyroid Carcinoma: Validation and Application of a Classifier for Prognostication
Stefano Christian Londero, Marie Louise Jespersen, Annelise Krogdahl, et al.
The Journal of Clinical Endocrinology and Metabolism
|
June 15, 2007
Improvement of goiter volume reduction after 0.3 mg recombinant human thyrotropin-stimulated radioiodine therapy in patients with a very large goiter: a double-blinded, randomized trial
Steen J Bonnema, Viveque E Nielsen, Henrik Boel-Jørgensen, et al.
The Journal of Clinical Endocrinology and Metabolism
|
July 31, 2008
Recombinant human thyrotropin-stimulated radioiodine therapy of large nodular goiters facilitates tracheal decompression and improves inspiration
Steen J Bonnema, Viveque E Nielsen, Henrik Boel-Jørgensen, et al.
British Journal of Cancer
|
May 26, 2025
Long-term clinical outcome of patients with metastatic melanoma and initial stable disease during anti-PD-1 checkpoint inhibitor immunotherapy with pembrolizumab
Inge Mansfield Noringriis, Marco Donia, Kasper Madsen, et al.
American Journal of Therapeutics
|
November 5, 2013
Side effects and toxicities of targeted therapies in stage IV melanoma
Paolo A Ascierto, Lars Bastholt, Peter Hersey, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 13, 2025
Impact of assessment-to-treatment interval and metastatic biopsy site on the predictive value of PD-L1 expression at the 1 % cut-off level in melanoma
Cecilie D Vestergaard, Marco Donia, Kasper Madsen, et al.
Page
of 14